Nemes Rush Group LLC Oncternal Therapeutics, Inc. Transaction History

Nemes Rush Group LLC

  • $689 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 02, 2023
BUY
$0.28 - $0.79 $19 - $56
71 New
71 $25,000

Others Institutions Holding ONCT

# of Institutions
3
Shares Held
362K
Call Options Held
0
Put Options Held
0
View Full List

About Oncternal Therapeutics, Inc.

ONCT Quotes by TradingView
  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $29.4M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track This Portfolio

Track Nemes Rush Group LLC Portfolio

Follow Nemes Rush Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nemes Rush Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nemes Rush Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email